BR112013027851A2 - métodos para identificar um indivíduo caucasiano e para determinar uma suscetibilidade do indivíduo caucasiano de ter ou desenvolver a degeneração macular relacionada com a idade, e, kit - Google Patents
métodos para identificar um indivíduo caucasiano e para determinar uma suscetibilidade do indivíduo caucasiano de ter ou desenvolver a degeneração macular relacionada com a idade, e, kitInfo
- Publication number
- BR112013027851A2 BR112013027851A2 BR112013027851A BR112013027851A BR112013027851A2 BR 112013027851 A2 BR112013027851 A2 BR 112013027851A2 BR 112013027851 A BR112013027851 A BR 112013027851A BR 112013027851 A BR112013027851 A BR 112013027851A BR 112013027851 A2 BR112013027851 A2 BR 112013027851A2
- Authority
- BR
- Brazil
- Prior art keywords
- caucasian individual
- methods
- caucasian
- susceptibility
- individual
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 206010064930 age-related macular degeneration Diseases 0.000 title abstract 2
- 208000002780 macular degeneration Diseases 0.000 title abstract 2
- 230000000295 complement effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/50—Detection characterised by immobilisation to a surface
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/50—Detection characterised by immobilisation to a surface
- C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161480929P | 2011-04-29 | 2011-04-29 | |
| PCT/US2012/035467 WO2012149329A2 (en) | 2011-04-29 | 2012-04-27 | Methods of predicting the development of complement-mediated disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013027851A2 true BR112013027851A2 (pt) | 2017-11-07 |
Family
ID=47073084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013027851A BR112013027851A2 (pt) | 2011-04-29 | 2012-04-27 | métodos para identificar um indivíduo caucasiano e para determinar uma suscetibilidade do indivíduo caucasiano de ter ou desenvolver a degeneração macular relacionada com a idade, e, kit |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20140357732A1 (enExample) |
| EP (1) | EP2704800B1 (enExample) |
| JP (1) | JP2014513958A (enExample) |
| KR (1) | KR20140074258A (enExample) |
| CN (1) | CN103874526A (enExample) |
| AU (1) | AU2012249521A1 (enExample) |
| BR (1) | BR112013027851A2 (enExample) |
| CA (1) | CA2834676A1 (enExample) |
| DK (1) | DK2704800T3 (enExample) |
| SG (1) | SG194235A1 (enExample) |
| WO (1) | WO2012149329A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
| JP6829878B2 (ja) * | 2017-03-10 | 2021-02-17 | 国立大学法人浜松医科大学 | 加齢黄斑変性の発症リスクの評価方法 |
| WO2020019002A1 (en) | 2018-07-20 | 2020-01-23 | University Of Utah Research Foundation | Gene therapy for macular degeneration |
| KR102333953B1 (ko) * | 2020-07-10 | 2021-12-02 | 인제대학교 산학협력단 | 신규한 황반변성 진단용 유전자 마커 |
| US12518859B2 (en) * | 2023-07-26 | 2026-01-06 | Helix, Inc. | Systems and methods for providing test results of gene sequencing data on a recurring basis |
| CN119694384B (zh) * | 2024-12-03 | 2025-10-03 | 南京医科大学 | 基于汇总统计数据的复杂性状关联基因检测方法及系统 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745389B2 (en) * | 2005-02-14 | 2010-06-29 | University Of Iowa Research Foundation | Methods for treatment of age-related macular degeneration |
| WO2006096561A2 (en) * | 2005-03-04 | 2006-09-14 | Duke University | Genetic variants increase the risk of age-related macular degeneration |
| DK2447275T3 (en) * | 2006-07-13 | 2015-06-29 | Univ Iowa Res Found | Methods and reagents for the treatment of age-related macular degeneration |
| WO2009059317A2 (en) * | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715 |
| US8114592B2 (en) * | 2008-03-18 | 2012-02-14 | Cambridge Enterprise Limited | Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof |
| WO2010075519A2 (en) * | 2008-12-23 | 2010-07-01 | Massachusetts Eye & Ear Infirmary | Allelic variants associated with advanced age-related macular degeneration |
| US20120202708A1 (en) * | 2010-10-14 | 2012-08-09 | Sequenom, Inc. | Complement factor h copy number variants found in the rca locus |
| WO2012082912A2 (en) * | 2010-12-14 | 2012-06-21 | Tufts Medical Center, Inc. | Markers related to age-related macular degeneration and uses therefor |
| BR112013023724A2 (pt) * | 2011-03-15 | 2019-09-24 | Univ Utah Res Found | métodos para tratar doença ou sintoma, detriagem para um agente ou uma combinação de agentes, e para determinar a eficácia de um agente e de um tratamento |
| EP2895624B1 (en) * | 2012-09-14 | 2022-06-01 | University Of Utah Research Foundation | Methods of predicting the development of amd based on chromosome 1 and chromosome 10 |
| US9896728B2 (en) * | 2013-01-29 | 2018-02-20 | Arcticrx Ltd. | Method for determining a therapeutic approach for the treatment of age-related macular degeneration (AMD) |
-
2012
- 2012-04-27 KR KR1020137031638A patent/KR20140074258A/ko not_active Withdrawn
- 2012-04-27 DK DK12776262.3T patent/DK2704800T3/en active
- 2012-04-27 JP JP2014508602A patent/JP2014513958A/ja active Pending
- 2012-04-27 CA CA2834676A patent/CA2834676A1/en not_active Abandoned
- 2012-04-27 EP EP12776262.3A patent/EP2704800B1/en active Active
- 2012-04-27 BR BR112013027851A patent/BR112013027851A2/pt not_active IP Right Cessation
- 2012-04-27 US US14/114,751 patent/US20140357732A1/en not_active Abandoned
- 2012-04-27 SG SG2013080502A patent/SG194235A1/en unknown
- 2012-04-27 WO PCT/US2012/035467 patent/WO2012149329A2/en not_active Ceased
- 2012-04-27 CN CN201280031235.6A patent/CN103874526A/zh active Pending
- 2012-04-27 AU AU2012249521A patent/AU2012249521A1/en not_active Abandoned
-
2017
- 2017-06-27 US US15/634,892 patent/US20180155788A1/en not_active Abandoned
-
2020
- 2020-01-03 US US16/734,168 patent/US20200239958A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG194235A1 (en) | 2013-12-30 |
| US20180155788A1 (en) | 2018-06-07 |
| CA2834676A1 (en) | 2012-11-01 |
| EP2704800A4 (en) | 2015-04-29 |
| AU2012249521A1 (en) | 2013-11-14 |
| EP2704800B1 (en) | 2018-09-12 |
| US20200239958A1 (en) | 2020-07-30 |
| EP2704800A2 (en) | 2014-03-12 |
| US20140357732A1 (en) | 2014-12-04 |
| DK2704800T3 (en) | 2019-01-14 |
| WO2012149329A2 (en) | 2012-11-01 |
| KR20140074258A (ko) | 2014-06-17 |
| WO2012149329A3 (en) | 2012-12-20 |
| JP2014513958A (ja) | 2014-06-19 |
| CN103874526A (zh) | 2014-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| CY1122907T1 (el) | Διαγνωστικες αναλυσεις και kit για ανιχνευση υποδοχεα φολικου 1 | |
| UY33826A (es) | Proteínas de unión con dominios trivariables y sus usos | |
| CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
| AR092818A1 (es) | Anticuerpo tau humanizado | |
| MX384191B (es) | Molecula de union al antigeno especifico para el tejido objetivo. | |
| BR112014018592A2 (pt) | composição e método para o diagnóstico e tratamento de doenças associadas à degeneração de neuritos | |
| BR112013004581A2 (pt) | imunoglobulinas de domínio variável dual e seus usos | |
| CY1117678T1 (el) | Ενωσεις αναστολεων μεταλλοενζυμου | |
| EA201400579A1 (ru) | Антитела к il-36r | |
| GT201200189A (es) | Antagonistas de pcsk9 | |
| CO6710903A2 (es) | Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo | |
| MX2014003832A (es) | Molecula de union al antigeno que induce la inmunorespuesta al antigeno objetivo. | |
| BR112015022821A2 (pt) | método para avaliar status renal em um indivíduo e kit de ensaio de diagnóstico | |
| BR112013022927A2 (pt) | composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição | |
| EA201490825A1 (ru) | Tdp-43-специфически связывающие молекулы | |
| AR092779A1 (es) | Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau | |
| TR201902439T4 (tr) | Fukoz analogları kullanarak in vivo protein fukosilasyonunun inhibisyon yöntemleri . | |
| WO2012094580A3 (en) | Compounds that modulate oxidative stress | |
| EA201590247A1 (ru) | Антитела к siglec-15 | |
| WO2012166626A8 (en) | Reagents and methods for treating dental disease | |
| EA201590630A1 (ru) | Способы лечения и диагностики, связанные с лизилоксидазоподобным белком 2 (loxl2) | |
| EA201400447A1 (ru) | АНТИТЕЛА К CD1d | |
| ECSP13012913A (es) | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) | |
| CY1120877T1 (el) | Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |